TY - JOUR
T1 - Bladder contractility is modulated by Kv7 channels in pig detrusor
AU - Svalø, Julie
AU - Bille, Michala
AU - Parameswaran Theepakaran, Neeraja
AU - Sheykhzade, Majid
AU - Nordling, Jørgen
AU - Bouchelouche, Pierre
N1 - © 2013 Elsevier B.V. All rights reserved.
PY - 2013/9/5
Y1 - 2013/9/5
N2 - Kv7 channels are involved in smooth muscle relaxation, and accordingly we believe that they constitute potential targets for the treatment of overactive bladder syndrome. We have therefore used myography to examine the function of Kv7 channels in detrusor, i.e. pig bladder, with a view to determining the effects of the following potassium channel activators: ML213 (Kv7.2/Kv7.4 channels) and retigabine (Kv7.2-7.5 channels). Retigabine produced a concentration-dependent relaxation of carbachol- and electric field-induced contractions. The potency was similar in magnitude to that of ML213-induced relaxation, suggesting that Kv7.2 and/or Kv7.4 channels constitute the subtypes that are relevant to bladder contractility. The effects of retigabine and ML213 were attenuated by pre-incubation with 10µM XE991 (Kv7.1-7.5 channel blocker) (P
AB - Kv7 channels are involved in smooth muscle relaxation, and accordingly we believe that they constitute potential targets for the treatment of overactive bladder syndrome. We have therefore used myography to examine the function of Kv7 channels in detrusor, i.e. pig bladder, with a view to determining the effects of the following potassium channel activators: ML213 (Kv7.2/Kv7.4 channels) and retigabine (Kv7.2-7.5 channels). Retigabine produced a concentration-dependent relaxation of carbachol- and electric field-induced contractions. The potency was similar in magnitude to that of ML213-induced relaxation, suggesting that Kv7.2 and/or Kv7.4 channels constitute the subtypes that are relevant to bladder contractility. The effects of retigabine and ML213 were attenuated by pre-incubation with 10µM XE991 (Kv7.1-7.5 channel blocker) (P
U2 - 10.1016/j.ejphar.2013.05.005
DO - 10.1016/j.ejphar.2013.05.005
M3 - Journal article
C2 - 23707187
SN - 0031-6970
VL - 715
SP - 312
EP - 320
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
IS - 1-3
ER -